pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,183 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1164Endpoints878BioPharma Dive339BioSpace298Fierce Biotech278onclive165raps104globenewswire health73
therapy area
allOncology7441Rare Disease1841Cardiology1688Immunology1467Hematology1306Vaccines1190Pulmonology
  • Health secretary RFK Jr. faces staffing gaps as top priority over vaccine initiatives
    Robert F. Kennedy Jr., in his second year as the nation’s health secretary, has spent much of the first half of the year traveling to farms, clinics and other sites across the United States. In in…
    STAT · 3mo agoNeutral↗ source
  • Study highlights gaps in male puberty research and links timing to future health risks
    Researchers note that most knowledge about puberty comes from studies in girls, leaving a substantial gap in understanding how the onset of puberty in boys affects later health. Emerging evidence…
    STAT · 3mo agoNeutral↗ source
← prev
page 70 of 88
next →
fda recalls67
fda medwatch60
fda press38
1106
Psychiatry & CNS862
Ophthalmology494
Pain473
Endocrinology & Metabolism466
Infectious Disease444
STAT reporter highlights diverse crowd and science at California longevity festival Vitalist Bay
Alex Hogan of STAT introduces a video dispatch about Sarah Todd's recent visit to Vitalist Bay, a longevity festival held in California. Todd reports that the event defies the common image of long…
STAT · 3mo agoNeutral↗ source
  • Bipartisan House bill would require security review of U.S. biotech investments in China
    A bipartisan group of Representatives introduced legislation on Tuesday that would expand the Committee on Investment and National Security (COINS) Act to cover biotechnology. The bill, called the…
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Eli Lilly partners with Ascidian Therapeutics on $1.9 b RNA exon-editing collaboration for kidney disease
    Eli Lilly and Boston-based Ascidian Therapeutics announced a research collaboration aimed at discovering medicines for genetically driven kidney diseases. The partnership leverages Ascidian’s RNA e…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Alnylam inks up to $2 billion AI partnership with Inceptive Nucleics for RNAi drug discovery
    Alnylam announced a three-year strategic collaboration with Inceptive Nucleics to develop AI foundation models for RNAi therapeutics. The agreement is valued at up to $2 billion, with an initial $…
    STAT · 3mo agoDealPositive↗ source
  • Highmark Health sues HaloMD over alleged sham arbitration letter and misleading price data
    Highmark Health, a Pennsylvania Blue Cross Blue Shield licensee with more than 7 million members, filed a complaint on June 1 in U.S. District Court in Western Pennsylvania accusing HaloMD of abusi…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NewLimit raises $435M Series C to launch epigenetic anti-aging therapy, while Lilly signs GLP-2 obesity drug deal
    Longevity startup NewLimit announced a $435 million Series C financing, one of the largest biotech rounds this year. The round was led by Founders Fund and included investors such as Thrive Capital…
    BioPharma Dive · 3mo agoNeutral↗ source
  • Legend Biotech shares jump 40% after promising early CAR-T data in Non-Hodgkin’s lymphoma
    Shares of Legend Biotech rose more than 40% after the company released early results from its in vivo CAR‑T therapy targeting Non‑Hodgkin’s lymphoma. The data showed encouraging activity and a mana…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Cigna to End Coverage of GLP-1 Weight-Loss Drugs Wegovy and Zepbound for Employees Starting July 1
    Cigna announced it will stop covering GLP-1 weight-loss medications for its employee health plan, effective July 1. The decision affects drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepboun…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NIH terminates $82 million outbreak research network, weakening pandemic preparedness
    In 2020 the National Institutes of Health created a network of ten centers to expand knowledge on re‑emerging and emerging infectious diseases. The program was funded with $82 million over five yea…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Trump administration's new Medicaid work-requirement rules surprise states and patients
    Medicaid leaders and advocates say they are shocked by the Trump administration's latest directives that tighten work‑requirement rules for the program, a shift from the tone of earlier federal sta…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NIH scientist and fellow charged with smuggling deactivated mpox virus into U.S.
    Two researchers at a U.S. government laboratory have been indicted for attempting to bring vials of deactivated mpox virus into the United States without proper authorization. The charges involve V…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Pope’s AI Encyclical Offers Guidance for Catholic Hospitals and Health Care
    The article notes that Pope Francis released an encyclical addressing artificial intelligence and examines what that means for Catholic hospitals and the broader health‑care system. STAT’s AI Prog…
    STAT · 3mo agoNeutral↗ source
  • Legend surges on early data for ‘in vivo’ lymphoma cell therapy
    Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Concerns arise that military practices may contribute to eating disorders amid broader health updates
    The Morning Rounds newsletter, written by Theresa Gaffney, raises a question about whether military environments are encouraging eating disorders. The piece is part of a daily health briefing that…
    STAT · 3mo agoNeutral↗ source
  • Researchers urge sweeping policy action on ultra-processed foods after poll shows bipartisan concern
    A special edition of the American Journal of Public Health brings together leading researchers on ultra-processed foods and delivers a clear message to policymakers: take action now. Food policy s…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Rising AI battle between hospitals and insurers drives soaring medical bills, says pediatric cardiologist
    Darshak Sanghavi, a pediatric cardiologist and chief medical officer of Machinify, writes an opinion piece about an emerging AI conflict between health providers and insurers over patient records a…
    STAT · 3mo agoNegative↗ source
  • Military culture may increase risk of eating disorders among men, expert warns
    Paula Chesley, a yoga and meditation instructor who works with people with eating disorders, notes that male clients are rare but many have served in the military. She says that, based on her expe…
    STAT · 3mo agoNegative↗ source
  • Public health must address the rapidly growing Amish population, experts say
    The STAT First Opinion podcast highlighted that the Amish community is expanding quickly, roughly doubling every two decades, which will increasingly affect public health planning. Researchers Bra…
    STAT · 3mo agoNeutral↗ source
  • Fulcrum Therapeutics considers sale after FDA blocks sickle cell drug development
    Fulcrum Therapeutics announced it is undertaking a strategic review that could lead to a sale after its lead sickle cell candidate, pociredir, was effectively blocked by the FDA. The agency cited…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • AbiVax shares plunge as safety concerns shadow strong ulcerative colitis trial results
    AbiVax reported Phase 3 data for its experimental therapy obefazimod in patients with moderately to severely active ulcerative colitis. Two dose levels achieved placebo‑adjusted clinical remission…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • ASCO 2026 Highlights Bispecific Antibodies, ADCs and New Advances in RAS-Targeted and Prostate Cancer Therapies
    The meeting featured a lively comparison of bispecific antibodies and antibody-drug conjugates as leading modalities in oncology. Researchers presented data suggesting that targeting mutant RAS pr…
    BioPharma Dive · 3mo agoPositive↗ source
  • Celcuity's gedatolisib trial cuts death risk but misses investor expectations
    Celcuity reported data from its Phase 3 VIKTORIA-1 trial evaluating gedatolisib in HR‑positive, HER2‑negative breast cancer with PIK3CA mutations. The trial enrolled 350 patients who had progresse…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Eli Lilly gives 340B hospitals a week to share data or lose drug discounts
    Eli Lilly has told hospitals and medical groups that participate in the 340B drug discount program that they must submit claims data for all Lilly medications by the coming Monday, or they will be…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source